Lariam

Država: Nova Zelandija

Jezik: angleščina

Source: Medsafe (Medicines Safety Authority)

Aktivna sestavina:

Mefloquine hydrochloride 274.09mg equivalent to mefloquine base 250mg

Dostopno od:

Pharmaco (NZ) Ltd

INN (mednarodno ime):

Mefloquine hydrochloride 274.09 mg (= mefloquine base 250mg)

Odmerek:

250 mg

Farmacevtska oblika:

Tablet

Sestava:

Active: Mefloquine hydrochloride 274.09mg equivalent to mefloquine base 250mg Excipient: Crospovidone ammonium calcium alginate Lactose monohydrate Magnesium stearate Maize starch Microcrystalline cellulose Poloxamer Purified talc

Enote v paketu:

Blister pack, 8 tablets

Razred:

Prescription

Tip zastaranja:

Prescription

Izdeluje:

Siegfried Evionnaz SA

Terapevtske indikacije:

Chemoprophylaxis, therapy and stand-by treatment of malaria. Chemoprophylaxis Chemoprophylaxis with Lariam is recommended for travellers to malarious areas, particularly those travelling to areas where there is a high risk of infection with strains of P. falciparum resistant to other antimalarials. Therapy Lariam is indicated for the oral treatment of malaria, particularly when caused by strains of P. falciparum resistant to other antimalarials. It may also be used for the treatment of P. vivax and mixed malaria. Stand-by treatment Lariam is also prescribed as a stand-by medication, to be carried by the traveller and self-administered as an emergency measure for suspected malaria when prompt medical attention is unavailable within 24 hours.

Povzetek izdelek:

Package - Contents - Shelf Life: Blister pack, - 8 tablets - 36 months from date of manufacture stored at or below 30°C. Store in original packge. Sensitive to moisture.

Datum dovoljenje:

1990-08-06

Navodilo za uporabo

Lariam
®
CMI 180918
1
New Zealand Consumer Medicine Information
LARIAM
®
_MEFLOQUINE HYDROCHLORIDE _
250 mg tablets
WHAT IS IN THIS LEAFLET
This leaflet answers some common questions about Lariam tablets.
It does not contain all the available information.
It does not take the place of talking to your doctor or pharmacist.
All medicines have risks and benefits. Your doctor has weighed the
risks of you taking Lariam
tablets against the benefits expected for you.
IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR
OR PHARMACIST.
KEEP THIS LEAFLET WITH THE MEDICINE.
You may need to read it again.
WHAT LARIAM IS USED FOR
Lariam contains the active ingredient mefloquine.
Lariam is used for the treatment and prevention of malaria,
particularly malaria caused by the
_Plasmodium falciparum _parasite resistant to other anti-malarial
medicines. It can also be used
as a stand-by treatment to be carried by the traveller and taken for
suspected malaria when
prompt medical attention is not available within 24 hours or more.
Lariam belongs to a group of medicines called quinolones (pronounced
_kwin-o-lones_).
Lariam works by killing the parasites that may cause or have caused
malaria.
_WHERE AND HOW YOU CAN CONTRACT MALARIA _
Malaria is an infectious disease that is widespread in tropical and
subtropical areas of Africa,
Latin America, Asia and countries around the Pacific. There are
different forms of malaria,
each of them caused by a specific parasite transmitted to humans by
the bite of the
Anopheles mosquito.
Lariam
®
CMI 180918
2
_PRECAUTIONS AGAINST MALARIA _
The best protection against malaria is to avoid mosquito bites. The
mosquito that causes
malaria
mainly
bites
between
dusk
and
dawn.
Therefore,
the
following
precautionary
measures are recommended:
•
during this period, wear light-coloured clothing that covers as much
of your skin as
possible.
•
apply mosquito repellent to your uncovered skin and to your clothes.
•
when sleeping in rooms that are not protected against mosquitoes, use
an effec

Lastnosti izdelka

NEW ZEALAND DATA SHEET
_ _
LARIAM001
07 DEC 2018
1
LARIAM
® 250 MG TABLETS
Mefloquine hydrochloride
1 PRODUCT NAME
Lariam 250 mg tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 tablet contains 274.09 mg racemic mefloquine hydrochloride,
equivalent to 250 mg mefloquine
base.
Excipient(s) with known effect: Lactose
For full list of excipients, see Section 6.1 List of excipients.
3 PHARMACEUTICAL FORM
Lariam 250 mg tablets are white, cross-scored cylindrical and biplane,
marked "RO", "C", "HE" and
an imprinted hexagon on one side.
4 CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Chemoprophylaxis, therapy and stand-by treatment of malaria.
_ _
CHEMOPROPHYLAXIS
Chemoprophylaxis with Lariam is recommended for travellers to
malarious areas, particularly those
travelling to areas where there is a high risk of infection with
strains of _P. falciparum_ resistant to
other antimalarials.
THERAPY
Lariam is indicated for the oral treatment of malaria, particularly
when caused by strains of _ P. _
_falciparum _ resistant to other antimalarials. It may also be used
for the treatment of _ P. vivax _ and
mixed malaria (see Section 4.2).
STAND-BY TREATMENT
Lariam
is
also
prescribed
as
a
stand-by
medication,
to
be
carried
by
the
traveller
and
self-
administered as an emergency measure for suspected malaria when prompt
medical attention is
unavailable within 24 hours.
4.2 DOSAGE AND ADMINISTRATION
Mefloquine has a bitter and slightly burning taste. Lariam tablets
should be swallowed whole, with
at least one glass of liquid. The tablets may be crushed and suspended
in a small amount of water,
milk or other beverage for administration to small children and other
persons unable to swallow
them whole.
NEW ZEALAND DATA SHEET
_ _
LARIAM001
07 DEC 2018
2
_CHEMOPROPHYLAXIS STANDARD DOSAGE _
The recommended chemoprophylactic dose of Lariam is approximately 5
mg/kg bodyweight once
weekly:
Bodyweight (kg)
Dose
5 – 20 kg
¼ tablet
> 20 – 30 kg
½ tablet
> 30 – 45 kg
¾ tablet
> 45 kg
1 tablet
Weekly doses should be taken regularly,